RESEARCH ARTICLE

Revision and Implementation of "Clinical Guideline for Tuberculosis and HIV in Prisons", Great Tehran Prison, Iran

Behnam Farhoudi¹, SeyedAhmad SeyedAlinaghi^{2,*}, Payam Tabarsi ³, Minoo Mohraz², Raheleh Golrokhy², Marzieh Farnia⁴, Mohammad Shahbazi⁵, Ramin Alasvand⁴, Bahman Ebrahimi⁴, Jafar Esfehani⁴ and Mehrzad Tashakoriyan⁴

¹Clinical Research Development Center, Amir-Almomenin Hospital, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran; ²Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran; ³Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁴Health and Treatment Office of Iranian Prisons Organization, Tehran, Iran and ⁵United Nations Development Program, Prisons Organization, Tehran, Iran

Abstract: *Aim:* To evaluate the feasibility of the revised "Clinical Guideline for HIV and TB" in the Great Tehran Prison during October 2013 to June 2014.

Methods: The guideline includes all aspects of HIV/TB gnosis based on active case finding (ACF), treatment and care services. **Before implementation**, a focus group discussion was conducted, and attended by experts or discussion, the guideline was revised.

The Great Tehran Prison contains three separate units; all prisoners are taken first to "reception and identification unit (*quarantine*)" and then send to two housing units according to their legal status.

An HIV ACF strategy was employed in the quarantine, and two units through a voluntary provider-initiated HIV testing. Three staffs of the triangular clinic trained the prisoners about common routes of HIV transmission and the symptoms of TB in the *units*. In the *quarantine*, all prisoners were examined for all HIV-risk factors, HIV testing and symptoms of TB. In unit one, healthcare staff continued the ACF process, while in unit two, the trained primers were assigned as the healthcare communicators to proceed with caution the steep. At this caring process, when the test result was positive, then the process of care, treatment and follow ups was initial Moreover, the use of *directly observed* (POTs) for antiretroviral therapy (ART) and TB was applied to the sick primers. There was also a follow-up caring for released prisoner to refer them to care and treatment services outside the prison.

Results: The guideline was implemented in the prison successfully.

Conclusion: **Regarding** feasibility of the guideline, the investigators of this study suggest that the guideline should be implemented in other prisons across the country.

ARTICLE HISTORY

Received: October 01, 2016 Revised: May 05, 2017 Accepted: May 05, 2017

DOI: 10.2174/1871526517666170518093529

Keywords: HIV, TB, Prison, Guideline, Implementation, Revision.

^{*}Address correspondence to this author at the Iranian Research Center for HIV/AIDS, Imam Khomeini Hospital, Keshavarz Blvd., Tehran, Iran; Tel/Fax: +98 (21) 66947984; E-mail: s_a_alinaghi@yahoo.com

1. INTRODUCTION

Tuberculosis (TB) is a major public health challenge and the most common cause of death in many settings particularly in the prisons of developing countries [1, 2]. The rate of TB transmission in prisons is 11 to 81 times higher than the general population [2]. Based on "guidelines for control of tuberculosis in prisons", five main factors are described to the contribution of the spread of TB in prisons. Prisons receive TB through offenders who are with higher risks of developing infections due to their prior conditions, such as malnutrition, abuse of alcohol and other drugs, previous imprisonment and poor socioeconomic status. Moreover, Prisons concentrate TB due to overcrowding, poor ventilation and inadequate access to treatment and care. Prisons disseminate TB by individuals with undetected TB who are transferred between different sections and Prisons make TB worse because of being delayed diagnosis and incomplete treatment and finally Prisoners export TB to general population through close contacts with prison staffs and visitors, and also after being released

TB infection control includes measurements with the aim of reducing the risk of TB transmission. The core element of such control plan is early identification of suspected patients and effective treatment [3].

In the recent years, a significant increase in the incidence of Pulmonary Tuberculosis (PTB) in prisons was reported both in the major industrialized countries and the developing countries [1, 4-8]. Large increases in rates of TB occurred by the HIV epidemic among intravenous drug users (IDU) in the prisons [9-13].

The rate of HIV infection among prisoners is much higher than the general population [3, 14, and 15]. Among Iranian population, imprisonment is one of the most frequent risk factors of HIV infection. In addition, HIV is the strongest risk factor for developing active TB of latent TB infection [14].

In Iran, the rate of TB incidence in prisons has been reported about ten times higher than the general population [16]. Likewise, HIV prevalence among prisoners in Iran is much higher than the general population. Estimated prevalence is about 1.4% (95%CI: %0.6-%2.2) in newest survey [17].

Due to the lack of practical guidelines for prisons in Iran, the main objective of this present study is to modify and implement the "Clinical Guideline for TB and HIV in Prisons" which is based on active case finding and to evaluate the feasibility of the revised guideline.

2. MATERIALS AND METHODS

2.1. Content of the Guideline

Guideline consists of different topics concerning TB, such as: TB action pressive case finding in prison, approving the tive TB, treatment of active TB in prison, monitoring of TB treatment, drug interactions and adverse effects, diagnosis and treatment of latent TB in prison, patients training, control of TB transmission in prison, and patient follow up after releasing the offender. Likewise, HIV topics included HIV testing at prison administration and in units, consultation after HIV testing and subsequent confirmation, evaluation of starting antiretroviral therapy, synchronization of anti-retroviral therapy and TB medications in prison, preventive therapy with Co-Trimoxazole and Azithromycine, monitoring adverse reactions and drug interaction in antiretroviral therapy (ART), patient training, follow up after releasing from primand finally evaluation and monitoring of the HI cograms.

2.2. Focus Group Discussion

A focus group discussion (FGD) was conducted on May 21st, 2013 with the purpose of identifying defects and limitation of the "Clinical Guideline for TB and HIV in Prisons". Fifteen people including officers of prisons' health care services, experts on jail diseases, a prison governor, a prison physician, and infectious disease specialists along with the executive director and project expert of the Global Fund participated in the FGD. Since FGDs are qualitative approaches, a targeted sampling was applied to recruit participants with enough experience on the field of TB/HIV control in prisons.

At the beginning of the interview, the participants were asked to complete a questionnaire on their demographic characteristics. During the interview, main researcher of the project, with helping of an educated facilitator, checked the accuracy of their interpretations from participants' responses by using some questions. Moreover, re-

searchers carefully monitored non-verbal means of communication such as body language and facial expressions. Participants were asked to clarify their remarks with examples, if necessary. Each discussion was recorded with prior permission by the participant. Complete transcriptions one interviews were also prepared. Main Criteria for iudgment on qualitative research were credibility, dependency, conformability and transferability.

erviews were analyzed through content analysis.

2.3. Setting

The Great Prison of Tehran is located outside the city of Tehran, with three separate units. All prisoners are first taken to "reception and identification unit (quarantine)" and then send to two housing units according to their legal status.

2.4. Process of Implementing "Clinical Guideline for TB and HIV in Prisons"

2.4.1. Infrastructural Modification

As a first step, the prison governors who were responsible for the prison settings were convinced for implementation of intervention in TB/HIV control. Then, one of the healthcare staffs (known as the TB/HIV communicator) was assigned as charge of the TB/HIV control programs. A vehicle was also provided for healthcare staffs to transport samples. In addition, TB isolation rooms were standardized and verified and small boxes were supplied for sputum specimens and tubes of HIV tests. Anti-TB and antiretroviral medications were provided adequately.

Division of boratory in the prison was asked to send the results of sputum smear and mycobacterium cultu western blot HIV test and ELISA screening reguarly using the telephone and also in written documents. The prisoners' data registration system was launched and the reports were organized in the archive of unit three. An independent phone line was connected for the triangular clinic. One of the important challenges to implement the guideline was the short duration of imprisonment. This was solved to some extent through some regulated follow ups after releasing prisoners, and a daily list of patients transferred between different units provided for the health care staff. In total, 70 letters were sent to ferent parts of the prison to indicate serious process and the ways to resolve them.

2.4.2. Training Sessions

Early TB/HIV case detection is necessary for TB and HIV infection control. Therefore, some training sessions were organized for different target groups in regards to specific roles they play in the implementation process of the "clinical guideline for TB and HIV in prisons". The training sessions were held from July 2013 to March 2014 (Table 1).

2.4.3. TB and HIV Diagnosis

- TB Active Case Finding: TB active case finding was started from October 2013. In the guarantine unit of the prison, two health care staffs initiated the ACF process by holding training sessions for prisoners three times a week. They introduced suspected cases of TB to the tugular clinic of the prison. ACF was done in two housing units. In unit one, the healthcare staff continued the ACF process, while in unit two; the trained prisoners were assigned as the healthcare communicators to proceed activity. The assigned persons were detective trained regarding to the ACF and HIV screening tests. The health communicators kept daily records of TB suspected cases and reported to the clinic.
- Each health care staff was encouraged to receive a limited low amount of cash reward for TB or HIV case findings.
- HIV Case Finding: An HIV screening test program was also launched in October 2013. HIV rapid test (Trinity Biotech Uni-Gold TM HIV; sensitivity and specificity of 100%) [18] was performed at the time of entrance. Quality control of the mentioned kit was performed each week according to national guideline [19]. The HIV case finding process continued in other units of the prison with two different approaches; Voluntary Provider-Initiated Testing and Voluntary Client-Initiated Testing. Prisoners were asked to identify different risk factors of HIV infection and given consultation. All people referred to the prison clinics were examined for the HIV infection if they had related risk factors ce the result was negative, they were given required information regarding prevention and risky behaviors. On the court, when the test was positive, process of care, treatment and follow-ups were initiated. If the test results

Table 1. Topics of the training sessions for the target groups regarding their roles in the prison.

Target group	Role in the process of implementing guideline	Topics of training sessions	
Health care staff (11 people)	Active and passive case finding	TB control programs	
		Early identification	
		Complete treatment	
		Follow up	
		Prevention	
		TB case finding	
		Passive case finding	
		Active case finding (ACF)	
		TB screening at the entry	
		Persistent case finding	
		ACF among HIV positive prisoners	
		ACF among those with close contact with TB infected people	
		Algorithm of TB Diagnosis	
		Taking history	
		Physical examination	
		Sputum smear and culture	
		Chest x-ray	
		Implementing DOT* strategy	
		Monitoring TB treatment	
		Anti-TB and anti-retroviral therapy	
		Identification of latent TB	
		Providing care after being released from prison	
		TB transmission control in prison	
		HIV rapid test	
		Consultation before and after HIV test	
		Patient education regarding TB and HIV infection	
Attorneys and health	Active and passive case finding	Importance of TB and HIV control in prisons	
care communicators (56		Early TB identification	
people)		TB clinical presentation	
and care providers (20 people)		Follow up	
реоріе)		Prevention	
		Direct supervision on the treatment	
		HIV testing guideline among prisoners	
		Identification of latent TB in HIV positive patients	
		Patient education regarding TB and HIV infection	
		Referring people with high risk factors for voluntary HIV testing	
Heads of prison's units and prison governor	Close cooperation	Importance of TB and HIV control in prisons	
Prison employees (10	Close cooperation	The whole process of implementing the guideline	
people)		Cost-effectiveness of early identification and treatment of patients	

^{*}Directly Observed Therapy

Table 2. Registration and reporting forms and the related checklist for implementation of the guideline.

Line list number1: HIV and TB active case finding among new prisoners in quarantine				
Line list number 2: HIV and TB active case finding among inward resident prisoners				
Line list number 3: Rapid HIV testing of prisoners				
Registration and following-up of antiretroviral therapy				
Follow-up and evaluation of patient with suspected tuberculosis				
Registration and following-up sputum samples				
Follow-up after release/transfer				
HIV and TB case finding (specialized for physician or the plan's observer)				
HIV counseling and testing				
Adherence to anti-tuberculosis and antiretroviral treatment				
Registration and following-up of tests (ELISA, Western Blot and CD4)				
Line list of counseling and HIV testing				
Line list of patients under antiretroviral therapy				
Line list of information about HIV positive prisoners				
Inquiries of prisoners outside the prison				
Line list of name of patients receiving anti-TB and antiretroviral therapy to deliver to healthcare reception				
Monitoring and evaluation checklist				

were inconclusive, the prison inmates were asked to get retested after two months.

- TB and HIV treatment services: Directly Observed Therapy (DOT) for TB was initiated on January 7th, 2014 and the antiretroviral Therapy (ART) plan was started on January 21th, 2014.
- Follow-up after release from the prison: All TB and HIV patients were followed-up after discharging from the prison. We introduced them to a healthcare network at nearest center of their residence, and emphasized both healthcare system and the patients to have adherence to treatment.

Briefly, the following figure shows the procedure of HIV/TB case finding, diagnosis and treatment in the Great Prison of Tehran with three different units. In unit one, TB/HIV communicator educated the prisoners about HIV risk factors and symptoms of TB, found suspected cases, completed line list of TB and HIV, and reported suspected cases to the triangular clinic as to further test and consultation. Accordingly, in unit two, a representative prisoners assigned as the health care communicator was responsible for educating other prisoners, case finding, completing preliminary line lists, and introducing to the triangular clinic. In the quarantine prices or unit three, all newly-transferred prisoners were admitted. On admission time, a nurse completed the health care certificate and line lists; however, in the bands (housing units). TB and HIV communicators did the same activity, and finally all suspected cases were referred to the triangular clinic.

In the triangular clinic, consultation and testing were performed to diagnose TB and HIV positive patients as shown in Fig. (1). Patients were examined by a general practitioner and, if necessary, they were referred to infectious disease specialist for further treatment. Moreover, the pral practitioner submitted some orders to a comics psychologist who was responsible for implementing orders, registration, monitoring of treatment and follow up activities after release.




Fig. (1). Process of TB/HIV case finding, diagnosis and treatment in the Great Prison of Tehran

3. RESULTS

Table 3 presents the FDG results regarding the guideline.

Table 4 shows the result of three different types of case finding in each unit of the prison. Active case finding is responsible for 98.4% of case finding.

The clinical guideline was performed in the prison successfully. So, implementation of the guideline was feasible in the prison.

4. DISCUSSION

Many different types of researches have mentioned using active case finding strategy in prison setting, with no explanation about operational ways for ACF. In this study, we described essential steps to have successful implementation of ACF in the prison based on the guideline.

Early diagnosis of positive TB patients captentially break the chain of transmission of https://example.com/bacterium tuberculosis to contacts [20] likewise to HIV. Incubation period of HIV is longer and the

Table 3. Important trends should be implemented to make the guideline applicable based on the experts' idea.

In the prison

-Education about TB and encouragement for active case finding and medical examination (e.g. by banners)

-Encouragement for taking medications and put awarding system for patients

-Established isolated rooms for TB patients

-Use peer groups for education and active case finding

Out of the prison

-Established a registry system and follow up the TB patients

-Obtaining prisoners' address before and after imprisonment

-Counseling and training patients about TB and HIV

-Communication with patient's family

-Introduction some healthcare centers to released prisoners

-Dedicating some advantages through prisoner supporting associations or healthcare centers

Table 4 Prisoners' distribution based on type and place of case finding in the Great Tehran Prison.

Place	Type of case finding*	Number	Percent
	Active	1452	50.77
Quarantine	Educationally active	335	11.71
	Passive	9	0.31
T 1	Educationally active	521	18.22
Type 1	Passive	34	1.19
T 2	Active	507	17.73
Type 2	Passive	2	0.07

delay is more. So we should choose a faster and more efficient way to find suspected cases between prisoners and general population. ACF can be employed as a supplementary approach to curtail diagnostic delay in high TB burden settings [20]. In this study, we used scientifically active case finding by conducting training sessions for prisoners. Training sessions were held by health care staffs or health communicators about TB symptoms and HIV risk factors to find TB/HIV suspected prisoners. By using this method, we could find 2815 prisoners who had HIV related behaviors and/or TB suspected symptoms.

An active case-finding survey in North Gondar Prison was carried out and a total of 250 prisoners were screened, among these, 26 (10.4%) prisoners were found to have TB. All the inmates who participated in the study volunteered for HIV testing and a total of 19 (7.6%) inmates were found to be reactive for the HIV antibody test amongst of which 9 (47.4%) had TB co-infection. The prevalence of HIV infection in the TB infected inmates was found to be 34.6% (9/26) [10].

According to one study in Malawi, the researchers used active case finding survey to investigate the rate of pulmonary tuberculosis in a large prison. Nine hundred fourteen (70%) of 1315 prisoners were screened [11]. Forty seven (5%) screened prisoners had pulmonary tuberculosis [21].

In another study from Zambia mass screening was performed by trained lay prison personnel, inmate peer educators and members of the local neighborhood health committees and could successfully screen prisoners [22]. Moreover, in Hong Kong for TB screening of long-stay prisoners, CXR screening, clinical examination, sputum bacteriology and serial CXR were done for those with abnormalities in CXR screening [23].

Some studies screened newly admitted prisoners for TB symptoms [10, 22, 24] in line with our study. In a study from Quebec to assess HIV prevalence, inmates were asked to participate in an anonymous survey concerning HIV infection. Volunteers answered a questionnaire and provided a saliva sample during a meeting with an interviewer [25] similar the way of study in Glenochil prison [26].

Due to the feasibility of the clinical guideline as a pilot project in the Great Tehran Prison, we can conclude that this guideline is an applicable and effective intervention tool. Therefore, it is suggested first to follow the implementation of this guideline prisons in Tehran and then within the whole country for improving the performance of triangular clinics in case finding and service delivery, which helps remarkably for detecting and controlling of TB/HIV prevalence in the country.

Limitations of this work include: the rapid transferring of the patients between different units cause difficulties in screening, diagnosis, testing, treatment and follow-ups. In addition, some prisoners with high-risk behaviors related to HIV and positive rapid diagnostic test were released from the prison before the confirmatory tests (ELISA, Western blot) completed. As the main index for being HIV positive approved by the ministry of health is western blot test, we faced some serious problems to follow-up those patients outside the prison.

The method used in this study provides significant opportunities to detect and follow up the treatment of HIV positive people and TB patients. The expansion of this method in other prisons in the country can significantly enhance the quality of service presentation. The application of active service presentation seems to be piloted for other diseases, and it can be developed in other prisons of the country, if performed successfully.

SUPPORTIVE FOUNDATIONS

This project was founded mainly by WHO office in Iran (resource of fund from Global Found to fight TB, AIDS and Malaria in prison Organization) to implement activities related to TB control and supplementary fund was provided by UNODC office in Iran to implement activities related to HIV.

INSTITUTIONAL REVIEW BOARD STATE-MENT

The study was reviewed and approved by institutional review board (IRB) of Tehran University of Medical Sciences.

CLINICAL TRIAL REGISTRATION STATE-MENT

This study is registered at http://research.tums.ac.ir/. The registration identification number is 9021598014.

INFORMED CONSENT STATEMENT

The prisoners provided verbal and written informed consent.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGMENTS

This study was part of a PhD dissertation supported by Tehran University of Medical Sciences (TUMS) (Grant No: 9021598014). We also thank all staffs in the Great Tehran Prison for their help.

REFERENCES

- [1] Buassano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F, Tuberclosis incidence in prisons: a systematic review. PloS Medicine. 2010;7(12):e1000381.
- [2] A. Aerts, B. Hauer, M. Wanlin, J. Veen. Tuberculosis and tuberculosis control in European prisons. International Journal of Tuberculosis and Lung Disease, 2006, 10(11):1215–1223.
- [3] Dara M *et al.* Guidelines for control of tuberculosis in prisons. Cambridge, MA, TB CAP, US Agency for International Development, 2009. Available at: http://pdf.usaid.gov/pdf_docs/PNADP462.pdf. Access date 17 November 2013.
- [4] Aerts A, Habouzit M, Mschiladze L, Malakmadze N, Sadradze N, Menteshashvili O, *et al.* Pulmonary tuberculosis in prisons of the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis. 2000; 4(12):1104–10.
- [5] Sretrirutchai S, Silapapojakul K, Palittapongarnpim P, Phongdara A, Vuddhakul V. Tuberculosis in Thai prisons: magnitude, transmission and drug susceptibility. Int J Tuberc Lung Dis. 2002; 6(3):208–14.
- [6] Hanau-Bercot B, Gremy I, Raskine L, Bizet J, Gutierrez MC, Boyer- Mariotte S, *et al.* A one-year prospective study (1994-1995) for a first evaluation of

- tuberculosis transmission in French prisons. Int J Tuberc Lung Dis. 2000; 4(9):853-9.
- [7] Kiter G, Arpaz S, Keskin S, Sezgin N, Budin D, Seref O. Tuberculosis in Nazilli District Prison, Turkey, 1997-2001. Int J Tuberc Lung Dis. 2003;7(2):153-8.
- Dubrovina I, Miskinis K, Lyepshina S, Yann Y, [8] Hoffmann H, Zaleskis R, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? Int J Tuberc Lung Dis. 2008: **12**(7):756–62.
- [9] Centers for Disease C, Prevention. Rapid assessment of tuberculosis in a large prison system--Botswana, 2002. MMWR Morb Mortal Wkly Rep. 2003; **52**(12):250-2.
- Moges B, Amare B, Asfaw F, Tesfaye W, Tiruneh M, Belyhun Y, et al. Prevalence of smear positive pulmonary tuberculosis among prisoners in North Gondar Zone Prison, northwest Ethiopia. BMC Infect Dis. 2012; 12:352.
- Noeske J, Kuaban C, Amougou G, Piubello A, Pouillot R. Pulmonary tuberculosis in the Central Prison of Douala, Cameroon. East Afr Med J. 2006; 83(1):25-
- [12] Moszynski P. Zambian prisons "threaten public health" because of high rates of TB and HIV. BMJ. 2010; **340**:c2225.
- Abebe DS, Bjune G, Ameni G, Biffa D, Abebe F. Prevalence of pulmonary tuberculosis and associated risk factors in Eastern Ethiopian prisons. Int J Tuberc Lung Dis. 2011;15(5):668-73.
- Nunn A, Cornwall A, Fu J, Bazerman L, Loewenthal H, Beckwith C. Linking HIV positive jail inmates to treatment, care and social services after release: results from a qualitative assessment of the COMPASS program. Journal of Urban Health. 2010;87(6):954-68
- Jurgens R, Nowak M, Day M. HIV and incarceration: prisons and detention. JIAS. 2011;14(1):1-17
- Biadglegne F, Rodloff AC, Sack U. Review of the prevalence and drug resistance of tuberculosis in prisons: a hidden epidemic. Epidemiol Infect, 2015; **143**(5): 887-900.
- Navadeh, S., et al., HIV prevalence and related risk [17] behaviours among prisoners in Iran: results of the na-

- tional biobehavioural survey, 2009. Sex Transm Infect, 2013. 89 Suppl 3: p. iii33-6.
- [18] Sensitivity and specificity of kits available at: www.trinitybiotech.com/PointOfCare/Pages/HIV-USA.aspx
- [19] Ministry of Health and Medical education, Health reference laboratory, guideline of using rapid test to detect HIV in Iran, 2013, unpublished
- J. Sekandi, D. Neuhauser, K. Smyth, C. Whalen, Ac-[20] tive case finding of undetected tuberculosis among chronic coughers in a slum setting in Kampala, Uganda, Int. J. Tuberc. Lung Dis. 13 (2009) 508-513.
- DS Nyangulu, MB, Prof AD Harries, MDcorrespond-[21] ence, C Kang'ombe, AE Yadidi, K Chokani, T Cullinan, MD, Tuberculosis in a prison population in Malawi. The Lancet, volume 350, No. 9087, p1284-1287.
- [22] Katie R Maggard, Sisa Hatwiinda, Jennifer B Harris, Winifreda Phiri, Annika Krüüner, Kaunda Kaunda, et al. Screening for tuberculosis and testing for human immunodeficiency virus in Zambian prisons. Bull World Health Organ. 2015; 93(2): 93-101.
- [23] Leung CC, Chan CK, Tam CM, Yew WW, Kam KM, Au KF. Chest radiograph screening for tuberculosis in a Hong Kong prison. Int J Tuberc Lung Dis. 2005; **9**(6):627-32.
- Saunders DL, Olive DM, Wallace SB, Lacy D, Leyba R, Kendig NE. Tuberculosis screening in the federal prison system: an opportunity to treat and prevent tuberculosis in foreign-born populations. Public Health Rep. 2001; 116(3):210-8.
- Dufour Annie, Alary Michel, Poulin Céline, Allard [25] Francine, Noël Lina, Trottier Germain, Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City. AIDS. 1996; **10**(9):1009-15.
- Sheila M Gore, AGraham Bird, Sheila M Burns, Da-[26] vid J Goldberg, Amanda J Ross, James Macgregor. Drug injection and HIV prevalence in inmates of Glenochil prison. BMJ 1995; doi: http://dx.doi.org/10.1136/bmj.310.6975.293 (Published 04 February 1995).